Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration

Matilde Tubertini; Luca Menilli; Celeste Milani; Cecilia Martini; Maria Luisa Navacchia; Marta Nugnes; Manuela Bartolini; Marina Naldi; Daniele Tedesco; Elisa Martella; Andrea Guerrini; Claudia Ferroni; Francesca Moret; Greta Varchi

doi:10.3389/fchem.2024.1443822

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration

Front Chem. 2024 Jun 18:12:1443822. doi: 10.3389/fchem.2024.1443822. eCollection 2024.

Authors

Affiliations

¹ Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Bologna, Italy.
² Department of Science and High Technology, University of Insubria, Como, Italy.
³ Pharmacy Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.
⁴ Department of Biology (DiBio), University of Padova, Padua, Italy.
⁵ Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.

Abstract

[This corrects the article DOI: 10.3389/fchem.2024.1378233.].

Keywords: IDO1 inhibition; carrier-free nanoparticles; chemotherapy; endogenous human serum albumin; prodrugs; triple-negative breast cancer; truncated evans blue.

Publication types

Published Erratum